Eric Shahinian - 28 Sep 2022 Form 4 Insider Report for Pasithea Therapeutics Corp. (KTTA)

Reporting relationship: Member of 10% owner group
Issuer ticker: KTTA
Reported as of: 28 Sep 2022
Net transaction value: +$76,299
SEC form: 4
Accepted by SEC: 30 Sep 2022, 16:36:00 UTC
Prior SEC filing: 06 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Eric Shahinian

Key filing fact

Eric Shahinian filed Form 4 for Pasithea Therapeutics Corp. (KTTA) on 30 Sep 2022.

Key facts

This page summarizes Eric Shahinian's Form 4 filing for Pasithea Therapeutics Corp. (KTTA).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 30 Sep 2022, 16:36.

Change

Previous filing in this sequence was filed on 06 Sep 2022.
Current net transaction value: +$76,299.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KTTA transaction

Common Stock

Purchase

Transaction value: $68,542
Shares: +57,647
Change %: +3.3%
Price: $1.19
Shares after: 1,781,705
Date: 28 Sep 2022
Ownership: See footnote
Footnotes: F1

KTTA transaction

Common Stock

Purchase

Transaction value: $7,757
Shares: +6,710
Change %: +0.38%
Price: $1.16
Shares after: 1,788,415
Date: 29 Sep 2022
Ownership: See footnote
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares are held by Camac Fund, LP. ("Camac Fund"). Eric Shahinian is the managing member of Camac Capital, LLC, which is the general partner of Camac Fund and the managing member of Camac Partners, LLC.